Inflammation and atrial fibrillation

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 246-247

  Hagiwara, Nobuhisa ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

DISEASE ASSOCIATION; EDITORIAL; ENDOCARDIUM; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; INFLAMMATION; MYOCARDITIS; PERICARDITIS;

ADAPTIVE IMMUNITY; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; CELL ADHESION; CELL MOVEMENT; ENDOCARDIUM; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; T-LYMPHOCYTES;

EID: 75749094814     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0986     Document Type: Editorial

References (12)

1. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525.
2. Verheule S, Sato T, Everett T 4th, Engle SK, Otten D, Rubart-von der Lohe M, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004; 94: 1458-1465.
3. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-3548.
4. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
5. Yamashita T, Sekiguchi A, Iwasaki Y, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262-270.
6. Aviles RJ, Martin DO, Pperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
7. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-767.
8. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51: 828-835.
9. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009; 73: 2244-2249.
10. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92.
11. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.
12. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-2336.